COVID-19 has changed our society – people are suffering, world economies have turned upside down and our life as we know it has changed forever. The treatment for COVID-19, when found, will bring a lot of value to society – but what price are we prepared to pay for this value? How do we make sure innovation in medicine continues to grow after this pandemic is over? And what incentives should society offer for current and future work in keeping us safe?
Join us on Tuesday, July 14 from 3:30 pm – 5 pm ET for a lively discussion with experts who have recently written articles addressing these questions:
Panelists include:
- Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council
- Sarah K. Emond, MPP, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review
- Craig Garthwaite, PhD, MPP, Herman R. Smith Research Professor in Hospital and Health Services, an Associate Professor of Strategy, and the Director of the Program on Healthcare, Kellogg School of Management, Northwestern University
- Peter K. Neumann, ScD, Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center; Professor of Medicine, Tufts University School of Medicine
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.